The AAPS Journal

, Volume 8, Issue 1, pp E20–E26 | Cite as

Genetic factors in the predisposition to drug-induced hypersensitivity reactions

Article

Abstract

Drug hypersensitivity reactions can occur with most drugs, although the frequency, severity, and clinical manifestations vary. Case reports have suggested that there may be familial clustering of drug hypersensitivity suggesting a genetiv predisposition. As with most other forms of drug response, predisposition to drug hypersensitivity reactions is likely to be multifactorial and multigenic. Given the immune pathogenesis of these reactions, it is perhaps not surprising that the most significant genetic associations have been identified in the major histocompatibility complex for drugs such as abacavir, carbamazepine, and allopurinol. For abacavir, it has been suggested that preprescription genotyping for HLA-B*5701 in whites may reduce the incidence of hypersensitivity. It is likely that as our knowledge of variation in the human genome improves, coupled with improvements in technology, many more significant genetic predisposing factors for drug hypersensitivity are likely to be identified in the next decade. However, as we search for these genetic factors, it is important that we do not forget environmental predisposition, and to bear in mind that a genetic marker for drug hypersensitivity in one population may not necessarily be relevant for another population. Notwithstanding the advances in genetic technologies, the ultimate determinant of success in this area of research will be the identification and careful phenotyping of patients with drug hypersensitivity reactions. As we progress to whole genome scanning, in order to satisfy the requirements for adequate statistical power, the identification of large numbers of carefully phenotyped patients will be feasible only through international collaborations.

Keywords

hypersensitivity pharmacogenetics drugs HLA polymorphisms 

References

  1. 1.
    Rawlins MD, Thompson JW. Mechanisms of adverse drug reactions. In: Davies DM, ed.Textbook of Adverse Drug Reactions. Oxford, UK: Oxford University Press, 1991:18–45.Google Scholar
  2. 2.
    Demoly P, Gomes ER. Drug hypersensitivities: definition, epidemiology and risk factors.Allerg Immunol (Paris). 2005;37:202–206.Google Scholar
  3. 3.
    Chadwick D, Shaw MDM, Foy P, Rawlins MD, Turnbull DM. Serum anticonvulsant concentration and the drug-induced skin eruptions.J Neurol Neurosurg Psychiatry. 1984;47:642–644.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Shear NH, Spielberg SP, Cannon M, Miller M. Anticonvulsant hypersensitivity syndrome: in vitro risk assessment.J Clin Invest. 1988;82:1826–1832.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Pirmohamed M, Naisbitt DJ, Gordon F, Park BK. The danger hypothesis: potential role in idiosyncratic drug reactions.Toxicology. 2002;181–182:55–63.CrossRefPubMedGoogle Scholar
  6. 6.
    Strachan DP, Wong HJ, Spector TD. Concordance and interrelationship of atopic diseases and markers of allergic sensitization among adult female twins.J Allergy Clin Immunol. 2001;108:901–907.CrossRefPubMedGoogle Scholar
  7. 7.
    Edwards SG, Hubbard V, Aylett S, Wren D. Concordance of primary generalized epilepsy and CBZ hypersensitivity in monozygotic twins.Postgrad Med J. 1999;75:680–681.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Johnson-Reagan L, Bahna SL. Severe drug rashes in 3 siblings simultaneously.Allergy. 2003;58:445–447.CrossRefPubMedGoogle Scholar
  9. 9.
    Peyrieere H, Nicolas J, Siffert M, Demoly P, Hallaire-Buys D, Reynes J. Hypersensitivity related to abacavir in 2 members of a family.Ann Pharmacother. 2001;35:1291–1292.CrossRefPubMedGoogle Scholar
  10. 10.
    Pellicano R, Silvestris A, Iannantuono M, Ciavarella G, Lomuto M. Familial occurrence of fixed drug eruptions.Acta Derm Venereol. 1992;72:292–293.PubMedGoogle Scholar
  11. 11.
    Gennis MA, Vemuri R, Burns EA, Hill JV, Miller MA, Spielberg SP. Familial occurrence of hypersensitivity to phenytoin.Am J Med. 1991;91:631–634.CrossRefPubMedGoogle Scholar
  12. 12.
    Spielberg SP, Gordon GB, Blake DA, Goldstein DA, Herlong HF. Predisposition to phenytoin hepatotoxicity assessed in vitro.N Engl J Med. 1981;305:722–727.CrossRefPubMedGoogle Scholar
  13. 13.
    Park BK, Pirmohamed M, Kitteringham NR. Idiosyncratic drug-reactions: a mechanistic evaluation of risk-factors.Br J Clin Pharmacol. 1992;34:377–395.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Pirmohamed M, Park BK. Genetic susceptibility to adverse drug reactions.Trends Pharmacol Sci. 2001;22:298–305.CrossRefPubMedGoogle Scholar
  15. 15.
    Perry HM, Tan EM, Carmody S, Sakamota A. Relationship of acetyl transferase activity to antinuclear antibodies and toxic symptoms in hypertensive patients treated with hydralazine.J Lab Clin Med. 1970;76:114–125.PubMedGoogle Scholar
  16. 16.
    Batchelor JR, Welsh KI, Tinoco RM, et al. Hydralazine-induced systemic lupus erythematosus: influence of HLA-DR and sex on susceptibility.Lancet. 1980;1:1107–1109.CrossRefPubMedGoogle Scholar
  17. 17.
    Naisbitt DJ, Pirmohamed M, Park BK. Immunopharmacology of hypersensitivity reactions to drugs.Curr Allergy Asthma Rep. 2003;3:22–29.CrossRefPubMedGoogle Scholar
  18. 18.
    Lander ES, Linton LM, Birren B, et al. Initial sequencing and analysis of the human genome.Nature. 2001;409:860–921.CrossRefPubMedGoogle Scholar
  19. 19.
    Venter JC, Adams MD, Myers EW, et al. The sequence of the human genome.Science. 2001;291:1304–1351.CrossRefPubMedGoogle Scholar
  20. 20.
    Tsunoda T, Lathrop GM, Sekine A, et al. Variation of gene-based SNPs and linkage disequilibrium patterns in the human genome.Hum Mol Genet. 2004;13:1623–1632.CrossRefPubMedGoogle Scholar
  21. 21.
    Walsh EC, Mather KA, Schaffner SF, et al. An integrated haplotype map of the human major histocompatibility complex.Am J Hum Genet. 2003;73:580–590.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Symonds W, Cutrell A, Edwards M, et al. Risk factor analysis of hypersensitivity reactions to abacavir.Clin Ther. 2002;24:565–573.CrossRefPubMedGoogle Scholar
  23. 23.
    Vittorio CC, Muglia JJ. Anticonvulsant hypersensitivity syndrome.Arch Intern Med. 1995;155:2285–2290.CrossRefPubMedGoogle Scholar
  24. 24.
    Hetherington S, McGuirk S, Powell G, et al. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir.Clin Ther. 2001;23:1603–1614.CrossRefPubMedGoogle Scholar
  25. 25.
    Mallal S, Nolan D, Witt C, et al. Association between presence ofHLA-B * 5701, HLA-DR7, andHLA-DQ3 and hypersensitivity to HIV-1 reverse transcriptase inhibitor abacavir.Lancet. 2002;359:727–732.CrossRefPubMedGoogle Scholar
  26. 26.
    Martin AM, Nolan D, Gaudieri S, et al. Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant.Proc Natl Acad Sci USA. 2004;101:4180–4185.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Hetherington S, Hughes AR, Mosteller M, et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir.Lancet. 2002;359:1121–1122.CrossRefPubMedGoogle Scholar
  28. 28.
    Hughes AR, Mosteller M, Bansal AT, et al. Association of genetic variations in HLA-B region with hyperensitivity to abacavir in some, but not all, populations.Pharmacogenomics. 2004;5:203–211.CrossRefPubMedGoogle Scholar
  29. 29.
    Hughes DA, Vilar FJ, Ward CC, Alfirevic A, Park BK, Pirmohamed M. Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity.Pharmacogenetics. 2004;14:335–342.CrossRefPubMedGoogle Scholar
  30. 30.
    Dodd CC, Naisbitt DJ, Vilar FJ, et al. Abacavir hypersensitivity in human immunodeficiency virus-positive patients: demonstration of the presence of drug-specific lymphocyte proliferation in vitro.Br J Clin Pharmacol. 2003;55:421.Google Scholar
  31. 31.
    Phillips EJ, Wong GA, Kaul R, et al. Clinical and immunogenetic correlates of abacavir hypersensitivity.AIDS. 2005;19:979–981.CrossRefPubMedGoogle Scholar
  32. 32.
    Walsh JS, Reese MJ, Thurmond LM. The metabolic activation of abacavir by human liver cytosol and expressed human alcohol dehydrogenase isozymes.Chem Biol Interact. 2002;142:135–154.CrossRefPubMedGoogle Scholar
  33. 33.
    Lindpaintner K. The importance of being modest: reflections on the pharmacogenetics of abacavir.Pharmacogenomics. 2002;3:835–838.CrossRefPubMedGoogle Scholar
  34. 34.
    Leeder JS. Mechanisms of idiosyncratic hypersensitivity reactions to antiepileptic drugs.Epilepsia. 1998;39:S8-S16.CrossRefPubMedGoogle Scholar
  35. 35.
    Rzany B, Correia O, Kelly JP, Naldi L, Auquier A, Stern R. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case-control study. Study Group of the International Case Control Study on Severe Cutaneous Adverse Reactions.Lancet. 1999;353:2190–2194.CrossRefPubMedGoogle Scholar
  36. 36.
    Mauri-Hellweg D, Bettens F, Mauri D, Brander C, Hunziker T, Pichler WJ. Activation of drug-specific CD4(+) and CD8(+) T cells in individuals allergic to sulfonamides, phenytoin, and CBZ.J Immunol. 1995;155:462–472.PubMedGoogle Scholar
  37. 37.
    Naisbitt DJ, Britschgi M, Wong G, et al. Hypersensitivity reactions to CBZ: characterization of the specificity, phenotype, and cytokine profile of drug-specific T-cell clones.Mol Pharmacol. 2003;63:732–741.CrossRefPubMedGoogle Scholar
  38. 38.
    Pirmohamed M, Kitteringham NR, Guenthner TM, Breckenridge AM, Park BK. An investigation of the formation of cytotoxic, protein-reactive, and stable metabolites from CBZ in vitro.Biochem Pharmacol. 1992;43:1675–1682.CrossRefPubMedGoogle Scholar
  39. 39.
    Tybring G, von Bahr C, Bertilsson L, Collste H, Glaumann H, Solbrand M. Metabolism of CBZ and its epoxide metabolite in human and rat liver in vitro.Drug Metab Dispos. 1981;9:561–564.PubMedGoogle Scholar
  40. 40.
    Kroetz DL, Kerr BM, McFarland LV, Loiseau P, Wilensky AJ, Levy RH. Measurement of in vivo microsomal epoxide hydrolase activity in white subjects.Clin Pharmacol Ther. 1993;53:306–315.CrossRefPubMedGoogle Scholar
  41. 41.
    Madden S, Maggs JL, Park BK. Bioactivation of CBZ in the rat in vivo: evidence for the formation of reactive arene oxide(s).Drug Metab Dispos. 1996;24:469–479.PubMedGoogle Scholar
  42. 42.
    Lertratanangkoon K, Horning MG. Metabolism of CBZ.Drug Metab Dispos. 1982;10:1–10.PubMedGoogle Scholar
  43. 43.
    Lillibridge JH, Amore BM, Slattery JT, et al. Protein-reactive metabolites of CBZ in mouse liver microsomes.Drug Metab Dispos. 1996;24:509–514.PubMedGoogle Scholar
  44. 44.
    Pirmohamed M, Graham A, Roberts P, et al. CBZ hypersensitivity: assessment of clinical and in vitro chemical cross-reactivity with phenytoin and oxcarbazepine.Br J Clin Pharmacol. 1991;32:741–749.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Gaedigk A, Spielberg SP, Grant DM. Characterization of the microsomal epoxide hydrolase gene in patients with anticonvulsant adverse drug reactions.Pharmacogenetics. 1994;4:142–153.CrossRefPubMedGoogle Scholar
  46. 46.
    Green VJ, Pirmohamed M, Kitteringham NR, et al. Genetic-analysis of microsomal epoxide hydrolase in patients with CBZ hypersensitivity.Biochem Pharmacol. 1995;50:1353–1359.CrossRefPubMedGoogle Scholar
  47. 47.
    Pirmohamed M, Lin K, Chadwick D, Park BK. TNFalpha promoter region gene polymorphisms in CBZ-hypersensitive patients.Neurology. 2001;56:890–896.CrossRefPubMedGoogle Scholar
  48. 48.
    Alfirevic A, Mills T, Harrington P, et al. Serious CBZ-induced hypersensitivity reactions associated with the HSP70 gene cluster.Pharmacogenetics and Genomics. In press.Google Scholar
  49. 49.
    Chung W-H, Hung S-I, Hong H-S, et al. Medical genetics: a marker for Stevens-Johnson syndrome.Nature. 2004;428:486.CrossRefPubMedGoogle Scholar
  50. 50.
    van der Linden PD, van der Lei J, Vlug AE, Stricker BH. Skin reactions to antibacterial agents in general practice.J Clin Epidemiol. 1998;51:703–708.CrossRefPubMedGoogle Scholar
  51. 51.
    Koopmans PP, van der Ven AJAM, Vree TB, van der Meer JWM. Pathogenesis of hypersensitivity reactions to drugs in patients with HIV-infection: allergic or toxic.AIDS. 1995;9:217–222.CrossRefPubMedGoogle Scholar
  52. 52.
    Rieder MJ, Shear NH, Kanee A, Tang BK, Spielberg SP. Prominence of slow acetylator phenotype among patients with sulfonamide hypersensitivity reactions.Clin Pharmacol Ther. 1991;49:13–17.CrossRefPubMedGoogle Scholar
  53. 53.
    Wolkenstein P, Loriot MA, Aractingi S, Cabelguenne A, Beaune P, Chosidow O. Prospective evaluation of detoxification pathways as markers of cutaneous adverse reactions to sulphonamides in AIDS.Pharmacogenetics. 2000;10:821–828.CrossRefPubMedGoogle Scholar
  54. 54.
    Pirmohamed M, Alfirevic A, Vilar J, et al. Association analysis of drug metabolizing enzyme gene polymorphisms in HIV-positive patients with co-trimoxazole hypersensitivity.Pharmacogenetics. 2000;10:705–713.CrossRefPubMedGoogle Scholar
  55. 55.
    Alfirevic A, Stalford AC, Vilar FJ, Wilkins EGL, Park BK, Pirmohamed M. Slow acetylator phenotype and genotype in HIV-positive patients with sulphamethoxazole hypersensitivity.Br J Clin Pharmacol. 2003;55:158–165.CrossRefPubMedPubMedCentralGoogle Scholar
  56. 56.
    Pirmohamed M, Naisbitt DJ, Park BK. The danger hypothesis: inflammation and idiosyncratic toxicity.Toxicology. 2001;164:5.Google Scholar
  57. 57.
    Palmer LJ, Cardon LR. Shaking the tree: mapping complex disease genes with linkage disequilibrium.Lancet. 2005;366:1223–1234.CrossRefPubMedGoogle Scholar
  58. 58.
    Hung SI, Chung WH, Liou LB, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol.Proc Natl Acad Sci USA. 2005;102:4134–4139.CrossRefPubMedPubMedCentralGoogle Scholar
  59. 59.
    Nunn P, Kibuga D, Gathua S, et al. Cutaneous hypersensitivity reactions due to thiacetazone in HIV-1 seropositive patients treated for tuberculosis.Lancet. 1991;337:628–630.CrossRefGoogle Scholar
  60. 60.
    Chintu C, Bhat GJ, Walker AS, et al. Co-trimoxazole as prophylaxis against opportunistic infections in HIV-infected Zambian children (CHAP): a double-blind randomised placebo-controlled trial.Lancet. 2004;364:1865–1871.CrossRefPubMedGoogle Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2006

Authors and Affiliations

  1. 1.Department of Pharmacology and TherapeuticsThe University of LiverpoolLiverpoolUK

Personalised recommendations